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Combination immune checkpoint inhibitor-induced hypophysitis:
A case report and review of the clinical and imaging findings
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Department of Radiology - Henry Ford Hospital, Detroit, Michigan

Figures

Goals and Objectives
1. Describe a case of immune-checkpoint inhibitor-induced
hypophysitis in a patient on combination immune checkpoint
inhibitor therapy for metastatic melanoma.
2. Discuss the imaging findings of autoimmune hypophysitis
associated with immune checkpoint inhibitors.
3. Familiarize the audience with the occurrence of this rare
complication of a novel therapy, so that it may be more
readily recognized.
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Introduction
Immune checkpoint inhibitors have emerged as a promising new
class of anti-cancer drugs. Unfortunately, while potentiating the
immune system’s response to cancer cells, these drugs also
place the patient at risk for the development of immune-related
adverse events (irAEs). Most often, the gastrointestinal tract and
skin are involved. However, involvement of the endocrine
system also occurs. While thyroid dysfunction is the most
common endocrinological irAE, hypophysitis is also frequently
seen - and is especially associated with ipilimumab (1).
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Discussion
CTLA-4 and PD1 are immune-checkpoint proteins involved in the
regulation of T-cell proliferation. Inhibition of these proteins
results in increased T-cell activation, which has shown positive
effects on the treatment of melanoma, although the mechanism
is not known (4). However, decreased regulation of T-cell
activation leads to less specific immune activity, which results in
immune-related adverse events (1).
Of these, panhypopituitarism can be one of the most profound.
Symptoms of combination immune checkpoint inhibitor therapy
induced autoimmune hypophysitis are variable and can include
headache, fatigue, hypopituitarism, and/or hyponatremia, as
were seen in this patient. Vision changes and other
endocrinopathies, such as type 1 diabetes and diabetes
insipidus, can also be seen, although was not present in this
case (2,5).
While hypophysitis can occur with ipilimumab alone (up to 17%
incidence), frequency and severity is greater when combined
with nivolumab (5). Treatment consists of discontinuation,
corticosteroids, and hormone replacement. Recovery of
hormone function, particularly of corticotrophins, is variable (1).

Case Presentation

Conclusion

A 60-year-old male undergoing combination immune checkpoint
therapy with nivolumab (an anti-PD-1 antibody) and ipilimumab
(an anti-CTLA-4 antibody) for metastatic melanoma developed
headaches. An MRI of the brain was obtained and
demonstrated new enlargement of the pituitary.
Initial differential considerations included a metastatic lesion to
the pituitary stalk, however the patient was also found to be
hypothyroid. Further endocrinological evaluation revealed low
testosterone, low random cortisol level, and low TSH,
consistent with pituitary insufficiency.
For management, checkpoint inhibitor therapy was held and the
patient was treated with prednisone 1mg/kg for 2 weeks, with
excellent clinical response, including resolved headaches and
improved energy. Follow-up MRI demonstrated resolution of the
pituitary enlargement.
Following resolution of initial symptoms, this patient was initially
resumed on single agent nivolumab, however due to
progression of disease was changed to trametinib (MEK
inhibitor antibody) and dabrafenib (BRAF inhibitor antibody) for
targeted BRAF mutated melanoma. At the time of this report,
the patient has had recurrence hypothyroidism and is
undergoing repeat endocrinological evaluation for recurrent
hypopituitarism.

As new cancer therapies emerge, physicians must remain aware
of the potential for unique adverse effects – such as those
occurring with immune checkpoint inhibitor therapies, including
hypophysitis. As the imaging appearance of hypophysitis is not
specific, understanding the clinical context in which it occurs can
aid radiologists in recognizing it as a possible diagnosis and help
guide appropriate clinical management.
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Sagittal pre-contrast MR images demonstrate a normal
appearance of the pituitary prior to initiation of the combination
checkpoint inhibitor therapy (A) and interval enlargement of the
pituitary approximately three months later near the end of the
combination therapy (B) with predominantly homogeneous
enhancement (D). A sagittal post-contrast T1 MR image following
checkpoint inhi0bitor therapy discontinuation and steroid
treatment demonstrates near resolution of the pituitary
enlargement (C) and symmetric enhancement (E).
This pattern of symmetric enhancement of the pituitary stalk with
resolution is characteristic of ipilimumab associated autoimmune
hypophysitis, but it is not specific (2,3).
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